

FAX

GlaxoSmithKline

To Art Unit 1625**Company** USPTO**Fax** 703-872-9307 703-308-4556**From** Valerie L. Phillips**Tel** 919-483-8223 **Fax** 919-483-5730**E-mail** Vlp47157@gsk.com**Date** April 15, 2003 **Pages including cover** 12**Subject** REFAXING RESPONSE AFTER FINAL OFFICE
ACTION

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

OFFICIAL**FAX RECEIVED**

APR 16 2003

GROUP 1600**Serial No.** 09/830,836**Filing Date:** May 1, 2001**Applicant:** Campbell et al.**Title:** Pyrazolopyridine Derivatives as Selective COX-2 Inhibitors**Examiner:** B. Robinson**Attached:**

Certificate of transmission via facsimile

COPY Auto-Reply Facsimile Transmission**COPY** Communication Result Report**COPY** Fax Memo to USPTO**COPY** Amendment Transmittal Letter**COPY** Response After Final (5 pages)**COPY** Certificate of Transmission

Thank you,

Valerie Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

TO: Auto-reply fax to 919 483 7988 COMPANY:

Auto-Reply Facsimile Transmission

UNITED STATES
PATENT AND
TRADEMARK OFFICE

TO:

Fax Sender at 919 483 7988

Fax Information

Date Received:

Total Pages:

2/25/03 10:35:58 AM [Eastern Standard Time]

8 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
Cover
Page

=====>

FEB 25, 2003 12:13PM PLAINFIELD NJ

NO. 7193 P. 1

FAX

To Group 1028
Company USPTO

Fax 703-672-6307

From Allison K. Jacobs

Tel 919-483-9105 **Fax** 919-483-7988

Email akj2723@uspto.gov

Date 25-Feb-2003 **Pages** including cover: 8

Subject Serial No.: 09/030,836

Filing Date: May 1, 2001

affected;
Amendment

gsk GlaxoSmithKline

GlaxoSmithKline Inc.
P.O. Box 15700
New York, NY 10157
New York, NY 10157
Fax: 919 483 7988
www.gsk.com

COPY

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee. If you have not been named as the addressee or have received this communication in error, please do not disseminate, copy, or otherwise use this information. If you have received this communication in error, please contact the sender immediately by telephone or return mail to the sender.

Received from 919 483 7988 on 2/25/03 10:35:58 AM [Eastern Standard Time]

APR. 15. 2003 2:19PM

GW GLOBAL R&D IS

NO. 7193 P. 4
P. 1

* * * COMMUNICATION RESULT REPORT (FEB. 25. 2003 12:15PM) * * *

TTI GLAXO WELLCOME

MODE	OPTION	ADDRESS (GROUP)	RESULT	PAGE
07 MEMORY TX		917038729307	OK	8/8

REASON FOR ERROR
E-1) HANG UP OR LINE FAIL
E-3) NO ANSWER

E-2) BUSY
E-4) NO FACSIMILE CONNECTION

copy

FAX**To** Group 1625**Company** USPTO**Fax** 703-872-9307**From** Allyson K. Jacobs**Tel** 919-483-9105**Fax** 919-483-7988**E-mail** akj27836@glaxowellcome.com**Date** 25-Feb-2003**Pages including cover** 8**Subject** Serial No.: 09/830,836

Filing Date: May 1, 2001


Glaxo Wellcome Inc.
PO Box 19398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Attached:

Amendment

Copy

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. PG3602USW							
Applicant(s): Campbell et al.											
Serial No. 09/830,836	Filing Date May 1, 2001	Examiner B. Robinson	Group Art Unit 1625								
Invention: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS											
<u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u>											
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.											
CLAIMS AS AMENDED											
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE						
TOTAL CLAIMS	20 -	20 =	0 x	\$18.00	\$0.00						
INDEP. CLAIMS	5 -	3 =	2 x	\$84.00	\$168.00						
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00						
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$168.00						
<div style="margin-top: 10px;"><input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed. <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392 A duplicate copy of this sheet is enclosed. <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</div>											
<div style="text-align: center;"> Signature Lorie Ann Morgan, Reg. No. 38,181 Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-8222 Facsimile: (919) 483-7988</div>			<div style="text-align: right;">Dated: 25 Feb 2003</div>								
<div style="text-align: center; font-size: 2em; font-weight: bold; transform: rotate(-10deg);">COPY</div>			<table border="1" style="width: 100%; border-collapse: collapse;"><tr><td colspan="2">I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.</td></tr><tr><td colspan="2" style="text-align: center;">Signature of Person Mailing Correspondence</td></tr><tr><td colspan="2" style="text-align: center;">Typed or Printed Name of Person Mailing Correspondence</td></tr></table>			I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.		Signature of Person Mailing Correspondence		Typed or Printed Name of Person Mailing Correspondence	
I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.											
Signature of Person Mailing Correspondence											
Typed or Printed Name of Person Mailing Correspondence											
CC:											

P11LARGE/REV06

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on 2/25/03
Date

Allyson K. Jacobs
Signature

Allyson K. Jacobs
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY

PG3602USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

I. Campbell et al.,

Serial No.: 09/830,836

Examiner: B. Robinson

Filing Date: 1 May 2001

Art Unit: 1625

For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Assistant Commissioner of Patents
Washington D.C. 20231RESPONSE AFTER FINAL

Sir:

Responsive to the final Office Action mailed 27 December 2002, please reconsider the instant application in view of the following remarks.

Remarks

Currently Claims 1-10, 13-14 and 17-35 are pending. Applicants acknowledge with appreciation the Examiner's indication that claims 1-9, 14, 18, 29 and 35 are allowed.

Informalities of the Outstanding Office Action

1. Status of Claim 10

The Office Action erroneously indicates that only claims 1-9, 14, 17-23 and 25-35 are pending. Applicants respectfully submit that the pending claims are 1-10, 14, 17-23 and 25-35. Claim 10 was indicated as allowable in the Office Action mailed 15 May 2002 and on page 4 of the outstanding Office Action. Accordingly, Applicants understand this claim to be properly pending and in allowable form. Confirmation of the status of this claim as both pending and allowable is respectfully requested.

COPY